SEC Form 4 · accession 0000899243-15-003020
Global Blood Therapeutics, Inc. · GBT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark L Perry
Director
Period of report
Aug 11, 2015
Accepted (ET)
Aug 13, 2015 · 12:15 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001629137
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2,F1 | $20.00 | Aug 11, 2015 | A | 15,000 | A | — | Aug 10, 2025 | Common Stock | 15,000 | 15,000 | D |
| Stock Option (right to buy)F2,F3 | $20.00 | Aug 11, 2015 | A | 8,600 | A | — | Aug 10, 2025 | Common Stock | 8,600 | 8,600 | D |
Explanation of responses
- F1The shares subject to this option shall vest and become exercisable in 12 equal monthly installments with the first installment on September 11, 2015, such that this option is fully exercisable on August 11, 2016. This option is subject to accelerated vesting upon a change of control of the Issuer.
- F2Not applicable.
- F3The shares subject to this option shall vest and become exercisable in 36 equal monthly installments with the first installment on August 23, 2015, such that this option is fully exercisable on July 23, 2018. This option is subject to accelerated vesting upon a change of control of the Issuer.